These mutation frequencies are broadly consistent with previous reports involving smaller cohorts of ~10,000 TCGA tumours of a variety of different cancers, which indicated that, among receptor tyrosine kinase and ERK1/2 pathway genes, KRAS (9% across all samples) is the most frequently altered gene, followed by BRAF (7%)17,28. The gene discussed is MAPK3; the disease is neoplasm.